The COVID-19 Diagnostics Market is witnessing important changes in testing delivery as healthcare providers and consumers increasingly seek convenient diagnostic solutions. Point-of-care testing, home care diagnostics, and online distribution are creating new opportunities beyond traditional centralized laboratory testing.

The global COVID-19 Diagnostics Market reached USD 7.876 billion in 2024 and is projected to grow from USD 8.184 billion in 2025 to USD 12.01 billion by 2035. The market is expected to expand at a CAGR of 3.91% during 2025–2035.

Hospitals currently represent the largest end-user segment, accounting for approximately 55% of the market. However, home care is gaining attention as patients increasingly prefer convenient testing options that can be performed outside traditional healthcare environments.

Point-of-care testing provides an important bridge between centralized laboratories and home-based diagnostics. These systems can deliver rapid results in hospitals, clinics, pharmacies, workplaces, and community settings. Faster results allow healthcare professionals to make timely decisions regarding patient management and infection-control measures.

Sample collection technologies are also evolving. Nasopharyngeal swabs currently represent the largest sample type, accounting for approximately 60% of the market. At the same time, saliva-based testing is attracting attention because it offers a less invasive collection method and may improve user convenience.

Distribution channels are changing alongside consumer behavior. Direct sales remain dominant, with approximately 58% share, particularly because hospitals and laboratories rely on established procurement networks. However, online sales are expanding as consumers become more comfortable purchasing healthcare products digitally.

The increasing integration of telehealth is further supporting decentralized testing. Virtual consultations can help patients obtain healthcare guidance remotely while connecting them with appropriate diagnostic services.

As healthcare systems prepare for future outbreaks and respiratory disease challenges, accessible diagnostic infrastructure will remain important. Manufacturers that combine speed, reliability, portability, and ease of use can benefit from changing testing preferences.

The continued development of point-of-care platforms, home diagnostics, digital healthcare, and convenient distribution channels is expected to contribute significantly to the long-term expansion of the COVID-19 Diagnostics Market.